Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma

• Status: Unknown status
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of this study is to evaluate the safety and the efficacy of an adult "acute lymphoblastic leukaemia" type chemotherapy in patients less than 60 years with lymphoblastic lymphoma. Treatment principle is based on an intensive induction and a delayed intensification.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Centre Henri Becquerel
• Treatments: Asparaginase; Cyclophosphamide; Cytarabine; Daunorubicin; Etoposide; Methotrexate; Prednisone; Vincristine

Criteria

Inclusion Criteria:

• Patient with lymphoblastic lymphoma.

• Aged from 18 to 59 years.

• Medullary blasts rate less than 20%

• Non previously treated

• With or without central nervous system or meningeal involvement.

• No contra-indication to anthracyclines.

• No contra-indication to intensive treatments

• Negative HIV serology test

• Negative pregnancy test for all female patients of childbearing potential.

• Able to be regularly followed up.

Exclusion Criteria:

• Evolutive cancer with the exception of non melanoma skin tumours or stage 0 (in situ) cervical carcinoma.

• Prior treatment with chemotherapy.

• Lymphoblastic Transformation of chronic myeloid leukaemia

• Patient unable to be regularly followed-up.